Vistin Pharma ASA (LON:0RAM)
London
· Delayed Price · Currency is GBP · Price in NOK 23.00
-2.40 (-9.45%)
At close: Apr 11, 2025
Vistin Pharma ASA Income Statement
Financials in millions NOK. Fiscal year is January - December.
Millions NOK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 440.66 | 429.5 | 435.39 | 287.68 | 275.81 | 253.16 | Upgrade
|
Other Revenue | - | - | 2.94 | 17.18 | 2.81 | 0.75 | Upgrade
|
| Revenue | 440.66 | 429.5 | 438.33 | 304.85 | 278.62 | 253.91 | Upgrade
|
Revenue Growth (YoY) | -0.14% | -2.01% | 43.78% | 9.41% | 9.74% | 11.30% | Upgrade
|
Cost of Revenue | 146.62 | 149.97 | 176.64 | 138.06 | 96.1 | 73.29 | Upgrade
|
Gross Profit | 294.04 | 279.53 | 261.68 | 166.79 | 182.53 | 180.62 | Upgrade
|
Selling, General & Admin | 95.96 | 94.22 | 81.84 | 69.73 | 64.96 | 64.34 | Upgrade
|
Other Operating Expenses | 83.98 | 80.99 | 93.9 | 90.88 | 73.71 | 61.1 | Upgrade
|
Operating Expenses | 199.16 | 194.24 | 193.09 | 172.88 | 149.28 | 135.06 | Upgrade
|
Operating Income | 94.88 | 85.3 | 68.6 | -6.1 | 33.25 | 45.56 | Upgrade
|
Interest Expense | -11.27 | -14.25 | -2.27 | -2.14 | -0.36 | -0.82 | Upgrade
|
Interest & Investment Income | 14.85 | 9.41 | 0.22 | 0.03 | 0.27 | 1.72 | Upgrade
|
Currency Exchange Gain (Loss) | - | - | -7.92 | 2.51 | -1.13 | -23.84 | Upgrade
|
Other Non Operating Income (Expenses) | 0.07 | 0.07 | -0.11 | -0.31 | -0.03 | -146.89 | Upgrade
|
EBT Excluding Unusual Items | 98.53 | 80.52 | 58.52 | -6.01 | 32 | -124.27 | Upgrade
|
Pretax Income | 98.53 | 80.52 | 58.52 | -6.01 | 32 | -124.27 | Upgrade
|
Income Tax Expense | 21.73 | 17.77 | 12.92 | -1.29 | 7.13 | -27.32 | Upgrade
|
Earnings From Continuing Operations | 76.79 | 62.75 | 45.6 | -4.72 | 24.87 | -96.96 | Upgrade
|
Net Income | 76.79 | 62.75 | 45.6 | -4.72 | 24.87 | -96.96 | Upgrade
|
Net Income to Common | 76.79 | 62.75 | 45.6 | -4.72 | 24.87 | -96.96 | Upgrade
|
Net Income Growth | 36.57% | 37.63% | - | - | - | - | Upgrade
|
Shares Outstanding (Basic) | 44 | 44 | 44 | 44 | 44 | 44 | Upgrade
|
Shares Outstanding (Diluted) | 44 | 44 | 44 | 44 | 44 | 44 | Upgrade
|
EPS (Basic) | 1.73 | 1.42 | 1.03 | -0.11 | 0.56 | -2.19 | Upgrade
|
EPS (Diluted) | 1.73 | 1.42 | 1.03 | -0.11 | 0.56 | -2.19 | Upgrade
|
EPS Growth | 36.57% | 37.63% | - | - | - | - | Upgrade
|
Free Cash Flow | 76.76 | 64.18 | 72.69 | -74.8 | -18.26 | -198.83 | Upgrade
|
Free Cash Flow Per Share | 1.73 | 1.45 | 1.64 | -1.69 | -0.41 | -4.48 | Upgrade
|
Dividend Per Share | 1.250 | 1.250 | 1.000 | 0.750 | 0.750 | 0.500 | Upgrade
|
Dividend Growth | 25.00% | 25.00% | 33.33% | - | 50.00% | -50.00% | Upgrade
|
Gross Margin | 66.73% | 65.08% | 59.70% | 54.71% | 65.51% | 71.14% | Upgrade
|
Operating Margin | 21.53% | 19.86% | 15.65% | -2.00% | 11.93% | 17.94% | Upgrade
|
Profit Margin | 17.43% | 14.61% | 10.40% | -1.55% | 8.92% | -38.19% | Upgrade
|
Free Cash Flow Margin | 17.42% | 14.94% | 16.58% | -24.54% | -6.55% | -78.31% | Upgrade
|
EBITDA | 114.1 | 104.33 | 84.89 | 5.33 | 42.79 | 54.28 | Upgrade
|
EBITDA Margin | 25.89% | 24.29% | 19.37% | 1.75% | 15.36% | 21.38% | Upgrade
|
D&A For EBITDA | 19.22 | 19.03 | 16.3 | 11.43 | 9.54 | 8.73 | Upgrade
|
EBIT | 94.88 | 85.3 | 68.6 | -6.1 | 33.25 | 45.56 | Upgrade
|
EBIT Margin | 21.53% | 19.86% | 15.65% | -2.00% | 11.93% | 17.94% | Upgrade
|
Effective Tax Rate | 22.06% | 22.07% | 22.08% | - | 22.28% | - | Upgrade
|
Revenue as Reported | - | - | 438.33 | 304.85 | 278.62 | 253.91 | Upgrade
|
Updated Feb 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.